Overview

Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus

Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Single arm phase II PDR001( 300mg, IV) will be treated every 3 weeks
Phase:
Phase 2
Details
Lead Sponsor:
Yonsei University
Treatments:
Antibodies
Spartalizumab